Gastroretentive drug delivery refers to approaches, formulation, manufacturing technique, storage systems, and technologies involved in transporting a pharmaceutical compound to its targeted site in gastro intestinal tract to achieve desired effect. Principles related to drug preparation, route of administration, site-specific targeting, metabolism, and toxicity are used to increase potency and safety of drug delivery system. The prevention and management of the disorder can be achieved by enhancing mucosal protection by gastroretentive drug delivery system. This system is used to advance oral delivering of drugs in the upper gastro intestinal tract can enhance oral bioavailability as well as therapeutic outcome.
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the gastroretentive drug delivery system market.
Top Impacting Factors
- Surge in cases of Helicobacter Pyroli infection, increase in hospital acquired infection cases, rise in demand for effective gastroretentive drug treatment, surge in awareness regarding gastro intestinal tract disease diagnosis, and rise in prevalence of chronic diseases are the major factors that drive the growth of the gastroretentive drug delivery system market.
- In addition, rise in adaptation of advance pharmaceutical drugs, ongoing research activity to enhance bioavailability of drugs, launch of novel & effective gastroretentive drugs in market, increase in usage of targeted drug therapies, scientific & technological advancement of healthcare sector through government funding, and aggressive marketing strategies by key market players are some factors, that fuel the growth of the gastroretentive drug delivery system market.
- However, side effects related to use of drugs and prolong need of treatment restrain the growth of the gastroretentive drug delivery system market.
- Contrarily, government initiatives regarding regulatory approvals and growth opportunities in emerging markets are expected to offer lucrative opportunities for the expansion of the market.
Market Trends
New Product Launches to Flourish the Market
In 2020, Cadila Pharmaceuticals announced launch Esomeprazole tablets. This tablets are used in treatment of hyperacidity & drug induced gastritis.
In 2020, Xiromed LLC launched 20mg Omperazole delayed release capsules. Omeprazole is cost effective generic product which can be used in treatment of gastroesophageal reflux disease and healing of erosive esophagitis.
Key Benefits of the Report
- This study presents the analytical depiction of gastroretentive drug delivery system market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the gastroretentive drug delivery system market share.
- The current market is quantitatively analyzed to highlight the gastroretentive drug delivery system market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Gastroretentive Drug Delivery System Market Report
- Which are the leading players active in the gastroretentive drug delivery system market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "gastroretentive drug delivery system"?
- What is "gastroretentive drug delivery system" market prediction in the future?
- Who are the leading global players in the "gastroretentive drug delivery system" market?
- What are the current trends and predicted trends?
- What are the key benefits of the "gastroretentive drug delivery system" market report?
Gastroretentive Drug Delivery System Market Report Highlights
| Aspects | Details |
 By Dosage Form |
|
 By Type |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | F. Hoffmann La Roche, Depomed Inc., Novartis AG, Alcon Inc., Pharmacia, Ranbaxy Laboratories, GlaxoSmithKline, Lupin Ltd, Galanix Co., Sun Pharmacautical |
Loading Table Of Content...
